These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36116377)

  • 1. Deficiency of kynurenine 3-monooxygenase exacerbates impairment of prepulse inhibition induced by phencyclidine.
    Kubota H; Kunisawa K; Niijima M; Hirakawa M; Mori Y; Hasegawa M; Fujigaki S; Fujigaki H; Yamamoto Y; Saito K; Nabeshima T; Mouri A
    Biochem Biophys Res Commun; 2022 Nov; 629():142-151. PubMed ID: 36116377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
    J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid.
    Mori Y; Mouri A; Kunisawa K; Hirakawa M; Kubota H; Kosuge A; Niijima M; Hasegawa M; Kurahashi H; Murakami R; Hoshi M; Nakano T; Fujigaki S; Fujigaki H; Yamamoto Y; Nabeshima T; Saito K
    Behav Brain Res; 2021 May; 405():113191. PubMed ID: 33607168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
    Tashiro T; Murakami Y; Mouri A; Imamura Y; Nabeshima T; Yamamoto Y; Saito K
    Behav Brain Res; 2017 Jan; 317():279-285. PubMed ID: 27693848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
    Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
    J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kynurenine monooxygenase inhibition and associated reduced quinolinic acid reverses depression-like behaviour by upregulating Nrf2/ARE pathway in mouse model of depression: In-vivo and In-silico studies.
    Bansal Y; Singh R; Sodhi RK; Khare P; Dhingra R; Dhingra N; Bishnoi M; Kondepudi KK; Kuhad A
    Neuropharmacology; 2022 Sep; 215():109169. PubMed ID: 35753430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variants of the kynurenine-3-monooxygenase and postpartum depressive symptoms after cesarean section in Chinese women.
    Wang SY; Duan KM; Tan XF; Yin JY; Mao XY; Zheng W; Wang CY; Yang M; Peng C; Zhou HH; Liu ZQ
    J Affect Disord; 2017 Jun; 215():94-101. PubMed ID: 28319697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia.
    Tufvesson-Alm M; Schwieler L; Schwarcz R; Goiny M; Erhardt S; Engberg G
    Neuropharmacology; 2018 Aug; 138():130-139. PubMed ID: 29879409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kynurenine pathway metabolic balance influences microglia activity: Targeting kynurenine monooxygenase to dampen neuroinflammation.
    Garrison AM; Parrott JM; Tuñon A; Delgado J; Redus L; O'Connor JC
    Psychoneuroendocrinology; 2018 Aug; 94():1-10. PubMed ID: 29734055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression.
    Chen Y; Zhang J; Yang Y; Xiang K; Li H; Sun D; Chen L
    J Cell Physiol; 2022 Dec; 237(12):4339-4355. PubMed ID: 36088660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases.
    Song P; Ramprasath T; Wang H; Zou MH
    Cell Mol Life Sci; 2017 Aug; 74(16):2899-2916. PubMed ID: 28314892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.
    Wonodi I; Stine OC; Sathyasaikumar KV; Roberts RC; Mitchell BD; Hong LE; Kajii Y; Thaker GK; Schwarcz R
    Arch Gen Psychiatry; 2011 Jul; 68(7):665-74. PubMed ID: 21727251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders.
    Erhardt S; Pocivavsek A; Repici M; Liu XC; Imbeault S; Maddison DC; Thomas MAR; Smalley JL; Larsson MK; Muchowski PJ; Giorgini F; Schwarcz R
    Biol Psychiatry; 2017 Nov; 82(10):756-765. PubMed ID: 28187857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum kynurenic acid is reduced in affective psychosis.
    Wurfel BE; Drevets WC; Bliss SA; McMillin JR; Suzuki H; Ford BN; Morris HM; Teague TK; Dantzer R; Savitz JB
    Transl Psychiatry; 2017 May; 7(5):e1115. PubMed ID: 28463241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.
    Oxenkrug G; van der Hart M; Roeser J; Summergrad P
    Integr Clin Med; 2017; 1(1):. PubMed ID: 28748226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.
    Holtze M; Saetre P; Engberg G; Schwieler L; Werge T; Andreassen OA; Hall H; Terenius L; Agartz I; Jönsson EG; Schalling M; Erhardt S
    J Psychiatry Neurosci; 2012 Jan; 37(1):53-7. PubMed ID: 21693093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothesis kynurenic and quinolinic acids: The main players of the kynurenine pathway and opponents in inflammatory disease.
    Badawy AA
    Med Hypotheses; 2018 Sep; 118():129-138. PubMed ID: 30037600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perinatal kynurenine 3-hydroxylase inhibition in rodents: pathophysiological implications.
    Ceresoli-Borroni G; Guidetti P; Amori L; Pellicciari R; Schwarcz R
    J Neurosci Res; 2007 Mar; 85(4):845-54. PubMed ID: 17279543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.